Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Indivior Pharmaceuticals (INDV) EBT Margin (2022 - 2026)

Indivior Pharmaceuticals has reported EBT Margin over the past 5 years, most recently at 36.28% for Q1 2026.

  • For Q1 2026, EBT Margin rose 1410.0% year-over-year to 36.28%; the TTM value through Mar 2026 reached 22.85%, up 2234.0%, while the annual FY2025 figure was 19.29%, 1761.0% up from the prior year.
  • EBT Margin for Q1 2026 was 36.28% at Indivior Pharmaceuticals, up from 22.63% in the prior quarter.
  • Over five years, EBT Margin peaked at 36.28% in Q1 2026 and troughed at 106.22% in Q4 2022.
  • A 5-year average of 3.99% and a median of 21.5% in 2023 define the central range for EBT Margin.
  • On a YoY basis, EBT Margin climbed as much as 12704bps in 2023 and fell as far as -9007bps in 2023.
  • Year by year, EBT Margin stood at 106.22% in 2022, then skyrocketed by 120bps to 20.82% in 2023, then crashed by -39bps to 12.75% in 2024, then soared by 77bps to 22.63% in 2025, then surged by 60bps to 36.28% in 2026.
  • Business Quant data shows EBT Margin for INDV at 36.28% in Q1 2026, 22.63% in Q4 2025, and 11.78% in Q3 2025.